In adoptive T-cell transfer models, CD8+ T cells treated with the ferroptosis inhibitor ferrostatin-1 can suppress tumor growth, whereas T cells treated with the ferroptosis inducer RSL-3 promote tumor growth [41]. This evidence concerns the gene CD8A and neoplasm.